Product portfolio

This page provides an outline of our current product portfolio. The content of the drug development portfolio will change over time as new compounds progress from development to the market.

You can also view an interactive version of our development pipeline, or alternatively you can download our development pipeline as a PDF (March 2013).

Our principal pharmaceutical products are presently directed to nine therapeutic areas. An analysis of sales by these therapeutic areas, and a description of the principal products, are set out below:

Turnover by therapeutic area 2013 £m 2012 £m
Respiratory 7,516 7,291
Central nervous system 1,483 1,670
Anti-virals 667 753
Anti-bacterials 1,239 1,247
Metabolic 174 171
Vaccines 3,420 3,325
Oncology and emesis 969 798
Cardiovascular and urogenital 2,239 2,431
Dermatology 770 850
ViiV Healthcare 1,386 1,374
Rare diseases 495 495
Immuno-inflammation 161 70
Other 799


  21,318* 22,112

* (excluding divestments completed during 2013, sales of the continuing pharmaceutical and vaccines portfolio was £20,972 million).

Products and their versions may not be approved for all indications in all markets where they are available.


Seretide/Advair, a combination of Serevent and Flixotide, offers a long-acting bronchodilator and an anti-inflammatory in a single inhaler. It is approved for the treatment of asthma and COPD.

Flixotide/Flovent and Beclovent are inhaled steroids for the treatment of inflammation associated with asthma and COPD.

Serevent is a long-acting bronchodilator used to treat asthma and COPD, and Ventolin is a selective short-acting bronchodilator used to treat bronchospasm.

Veramyst/Avamys, Flixonase/Flonase and Beconase are intra-nasal preparations for the treatment of perennial and seasonal rhinitis.

In 2013, GSK received approval for Breo Ellipta for COPD in the US and for COPD and asthma in Europe and approval for Anoro Ellipta in the US for COPD.

Central nervous system (CNS)

Seroxat/Paxil is a selective serotonin re-uptake inhibitor (SSRI) for the treatment of major depressive disorder, panic, obsessive compulsive disorder, post traumatic stress disorder, social anxiety disorder, premenstrual dysphoric disorder, and general anxiety disorder. A controlled release forumulation, Paxil CR, is available in the USA.

Wellbutrin is an anti-depressant, available in the USA and many European and international markets in normal, sustained-release (SR) and once daily (XL) formulations.

Imigran/Imitrex is a 5HT1 receptor agonist used for the treatment of severe or frequent migraine and cluster headache, and has become the reference product in this sector. Naramig/Amerge is also a 5HT1 receptor agonist indicated for the treatment of migraine.

Lamictal, a well established treatment for epilepsy, is also indicated for bipolar disorder.

Requip is a specific dopamine D2/D3 receptor agonist indicated for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS).


In November 2009, GSK's HIV/AIDS medicines became the property of ViiV Healthcare.

Zeffix has been approved for marketing in the USA, Europe, China and other markets for the treatment of chronic hepatitis B.

Valtrex is a treatment for episodic genital herpes as well as the long term suppression and reduction of transmission of genital herpes, zoster (shingles), cold sores and chicken pox. Valtrex supersedes Zovirax , which is also used to treat herpes infections.

Relenza is an anti-viral used to prevent and treat influenza.


Augmentin is a broad-spectrum antibiotic suitable for the treatment of a wide range of common bacterial infections and is particularly effective against respiratory tract infections. Augmentin ES-600 is an extra strength suspension specifically designed to treat children with recurrent or persistent middle ear infections.

Augmentin XR is an extended release formulation for the treatment of patients with community acquired pneumonia or acute bacterial sinusitis.

Altabax/Altargo, approved in 2007 for the topical treatment of certain bacterial skin infections, represents the first new class of topical antibiotics approved by the FDA in nearly two decades.

Ceftin/Zinnat is an oral antibiotic used primarily for community acquired infections of the lower respiratory tract.


Avandia is a potent insulin sensitising agent which acts on the underlying pathophysiology of type 2 diabetes. For more information about Avandia and associated products, visit our media resources section.


GlaxoSmithKline markets over 30 vaccines worldwide, of which more than half are combination vaccines to protect children, adolescents and/or adults against up to six diseases at the same time.

Cervarix is a vaccine intended to protect females against the diseases caused by infection with Human Papillomavirus (HPV) types 16 and 18. These diseases include cervical cancer and precancerous cervical lesions. A two-dose schedule of Cervarix was approved in EU during 2013.

Infanrix is a range of paediatric vaccine combinations. Infanrix provides protection against diphtheria, tetanus and pertussis (whooping cough). Infanrix penta (Europe) / Pediarix (USA and Canada) provides additional protection against hepatitis B and polio, and Infanrix hexa further adds protection against Haemophilus influenzae type b, which causes meningitis. Boostrix is available to add protection against pertussis (whooping cough) to the routine tetanus/diphtheria booster administered to teenagers.

In GSK's hepatitus range, Havrix protects against hepatitis A and Engerix-B against hepatitis B.

Twinrix is the only available combined hepatitis A and B vaccine, protecting against both diseases with one vaccine and available in both adult and paediatric strengths. In Europe, FENDrix, a vaccine to prevent hepatitis B in patients with renal insufficiency including high-risk groups such as pre-haemodialysis and haemodialysis patients, is available is available from 15 years of age onwards.

GSK added Fluviral to its portfolio of products when it acquired the Canadian vaccine manufacturer ID Biomedical Corporation in December 2005. Fluviral is marketed in Canada and, following FDA approval, the USA where it is approved for the active immunisation of adults 18 years and older against infl uenza disease under the brand FluLaval. Fluviral and FluLaval add to Fluarix GSK’s seasonal ‘flu vaccine, which is distributed in 79 countries including the USA.

GSK also markets Priorix, a measles, mumps and rubella vaccine, Typherix, a vaccine for protection against typhoid fever, and Varilrix, a vaccine against varicella or chicken pox. Priorix-Tetra, GSK’s new combination vaccine to prevent measles, mumps, rubella and varicella (MMRV) was first launched in Germany in August 2006.

In addition, the Group markets a range of vaccines to prevent meningitis under the umbrella name Mencevax. GSK’s new Hib- MenC vaccine, Menitorix is now available in the UK. GSK’s meningitis vaccine portfolio expanded in 2012 with the approval of Nimenrix and MenHibrix, two new paediatric medicines.

As part of its paediatric franchise, GSK continued to roll out the launch of its vaccine against rotavirus induced gastroenteritis, Rotarix, which is now launched in 90 countries worldwide. Rotavirus vaccination has been included in the national vaccination calendar of fi ve Latin American countries where Rotarix will be available free at public health clinics, as part of governmental paediatric immunisation programmes. In 2013, GSK introduced quadrivalent influenza vaccine presentations of Fluarix and FluLaval.

Oncology and emesis

Arzerrra is a CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.

Promacta/Revolade, is an oral treatment for thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia. In 2013, Revolade was approved in Europe for thrombocytopenia associated with hepatitis C

Tykerb is an oral treatment for patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab. Tykerb was approved in the USA in 2007 and is available in Europe, where it is known as Tyverb. 2013, Tyverb was approved in Europe for dual inhibition with Herceptin.

Votrient is an oral kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma or patients with advanced soft tissue sarcoma who have received prior chemotherapy.

GSK introduced Mekinist and Tafinlar, two new targeted therapies for metastatic melanoma, during 2013.

Cardiovascular and urogenital

Coreg is an alpha/beta blocker which has been proven to be effective in treating patients with mild, moderate and severe heart failure, heart attack or hypertension. GSK has sole marketing rights in the USA and Canada. A controlled release formulation, Coreg CR is also available in the USA. Generic versions of Coreg are available in the USA and Canada.

Avodart is a 5-ARI inhibitor currently indicated for benign prostatic hyperplasia.

Lovaza is a combination of ethyl esters of omega 3 fatty acids, principally EPA and DHA, indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.


Our dermatology portfolio includes heritage GSK products (e.g. Betnovate, Dermovate, CutivateBacrobanDuac and Zovirax) and those acquired through business acquisitions, principally Stiefel in July 2009.

A low dose version of Duac was approved in Europe for use in acne during 2013.

Rare diseases

GSK has a standalone unit specialising in the development and commercialisation of medicines for rare diseases. Over 5,500 rare diseases have been identified of which less than 10% are currently being treated, presenting a significant unmet medical need.


Relafen is a non-steroidal anti-inflammatory drug for the treatment of arthritis. Zantac is for the treatment of peptic ulcer disease and a range of gastric acid related disorders.